
argenx SE has unveiled promising data from its Phase 3 ADHERE trial, showcasing VYVGART® Hytrulo's potential as a groundbreaking treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). Presented at the American Academy of Neurology (AAN) Annual Meeting, the study highlights rapid clinical improvements and a significant reduction in relapse risk with VYVGART Hytrulo compared to a placebo. Furthermore, real-world data suggest a significant reduction of steroid use among generalized myasthenia gravis (gMG) patients following VYVGART treatment. The FDA is anticipated to make a decision on VYVGART Hytrulo for CIDP treatment by June 21, 2024.
Like
Save
Share